KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Acquisitions & Divestments: 2011-2024

Historic Change in Acquisitions & Divestments for Pacira BioSciences (PCRX) over the last 14 years, with Dec 2024 value amounting to $179.6 million.

  • Pacira BioSciences' Change in Acquisitions & Divestments rose 62.23% to $86.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $273.6 million, marking a year-over-year increase of 62.16%. This contributed to the annual value of $179.6 million for FY2024, which is 24.25% down from last year.
  • Latest data reveals that Pacira BioSciences reported Change in Acquisitions & Divestments of $179.6 million as of FY2024, which was down 24.25% from $237.1 million recorded in FY2023.
  • Over the past 5 years, Pacira BioSciences' Change in Acquisitions & Divestments peaked at $1.1 billion during FY2021, and registered a low of $179.6 million during FY2024.
  • Its 3-year average for Change in Acquisitions & Divestments is $218.1 million, with a median of $237.1 million in 2023.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first skyrocketed by 247.14% in 2021, then tumbled by 77.77% in 2022.
  • Yearly analysis of 5 years shows Pacira BioSciences' Change in Acquisitions & Divestments stood at $307.9 million in 2020, then skyrocketed by 247.14% to $1.1 billion in 2021, then crashed by 77.77% to $237.6 million in 2022, then decreased by 0.21% to $237.1 million in 2023, then declined by 24.25% to $179.6 million in 2024.